Floatz Rating
B57/100
Confidence
Indicative
Sponsor
ARCAGY/ GINECO GROUP
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03651206CT.gov Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dostarlimab (this asset) | ARCAGY/ GINECO GROUP | P2/3 | B · 57 |
| Cyclophosphamide | Mayo Clinic | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | BB |
| Carboplatin | University of Oklahoma | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P2 | B |
| Isocyclophosphamide | GOG Foundation | P3 | B |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | B |
| Pembrolizumab | Mayo Clinic | P2 | B |
| Niraparib | ARCAGY/ GINECO GROUP | P2/3 | B |
+26 more in the Ovarian Carcinosarcoma cohort
Other indications for Dostarlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 68 |
| Ovarian Carcinoma | — | P3 | BB · 65 |
| Colonic Neoplasm | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dostarlimab in Ovarian Carcinosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dostarlimab-ovarian-carcinosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →